Compare IONQ Inc (IONQ) vs Novo Nordisk A/S (NVO) Price & Performance

IONQ stock trades at $44.43, up 11.86% in 24 hours, with a bullish technical signal and strong revenue growth of 287% year-over-year in Q2 2026. The company reported a Q2 EPS miss but revenue beat, raised its 2026 outlook, and secured a $28 million defense contract. Valuation ratios are elevated with a P/E of 102.38 and P/S of 59.02, while profitability remains negative with a net income margin of -553.27% in 2026.

Outlook is optimistic due to quantum computing demand and analyst consensus price target of $73.33, but risks include high cash burn, intense competition, and reliance on speculative technology. Investors should weigh growth potential against persistent losses and dilution concerns from recent share issuance.

Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.

Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.